Recipharm, a global CDMO, is partnering with Ahead Therapeutics, a Spanish start-up biotech company, to develop treatments for autoimmune disorders, including a treatment for a rare autoimmune disease, myasthenia gravis. Recipharm will provide analytical and process development capabilities to support toxicology studies, as well as GLP manufacturing of lipid nanoparticles to encapsulate the active pharmaceutical ingredient, an antigen peptide. Recipharm also offers the capacity to scale up ma...